Abbott, St. Jude Medical re-up ‘cardiovascular alliance’ | Wall Street Beat

MassDevice.com Wall Street Beat

Abbott (NYSE:ABT) and St. Jude Medical (NYSE:STJ) are renewing and expanding an alliance to co-market their cardiovascular products, including Abbott’s market-leading Xience coronary stent line.

The deal, which extends a pact the companies inked in 2008, also includes St. Jude’s line of cardiac rhythm management, electrophysiology and cardiology products.

Sign up to get our free newsletters delivered straight to your inbox

It will see Abbott and St. Jude jointly promote the other’s product offerings to U.S. hospital customers, according to a press release, and includes a separate agreement giving Abbott U.S. distribution rights for St. Jude’s hybrid Ilumien FFR/OCT platform and its RadiAnalyzer Xpress system.

 Analyst: Thoratec, HeartWare to split the LVAD market
Thoratec (NSDQ:THOR) and HeartWare International (NSDQ:HTWR) are likely to carve out a 50-50 split of the market for left ventricular assist devices, at least for the next few years, according to "a high-volume EU cardiothoracic surgeon" from "1 of the largest LVAD implanting centers worldwide."

Leerink Swann analysts grilled the doc over the state of the LVAD market overseas, according to a research note to investors, coming away with 3 key points:

  1. “International LVAD market growth is poised to continue at a sustainable low-to-mid-teens pace for the next few years"
  2. "Thrombus concerns with HeartWare’s HVAD – which initially arose at last year’s ISHLT meeting – have eased significantly, at least amongst physicians"
  3. "International competitive dynamics appear basically stable with major shifts in market share for THOR/HTWR seemingly unlikely in the near-term, in line with our basically 50%/50% split through 2015"

HTWR shares plunged after concerns over higher blood clot rates surfaced last year, but the physician interviewed by Leerink said the concerns came as a surprise to cardiac surgeons, prompting initial caution that quickly eased, according to the note.

"But after looking at data specific to his center, he found a 3.5%  thrombus rate with HVAD – basically in line with the low-single-digit rate that Thoratec’s HeartMate II has historically generated. And he cited other centers with HVAD thrombus rates in the 3%-5% range,  but ‘never exceeding 5%,’" the researchers wrote. "Still, he did also note that patient selection and post-operative patient management with HVAD played  a meaningful role in driving that lower thrombus rate. With HVAD, patients at his practice receive heparin post-operation vs. none with HeartMate II."
Read more

 Arrhythmia Research releases Q1 prelims
Arrhythmia Research Technology (NYSE:HRT) said it was unable to file its annual report with the SEC by its April 16 deadline "due to an ongoing internal review by the Audit Committee and auditors relating to the adjustments to the calculation of the tax deferred assets in the company’s Canadian subsidiary, RMDDx Corp.," according to a regulatory filing.

Arrhythmia Research said it expects to post preliminary revenues of $24.3 million and net losses of $1.7 million.
Read more

 ETView Medical inks Taiwan distribution deal

ETView Medical (TLV:TLV) inked a 2-year distribution deal with Champ Medics Co. to market its VivaSight airway management platform in Taiwan.
Read more

 DeHaier Medical in Chinese distribution deal with Timesco
Dehaier Medical Systems (NSDQ:DHRM) signed a 3-year distribution pact to sell Timesco of London’s Optima laryngoscope in China.
Read more

 Nephros licences filtration tech from Medica
Nephros (OTC:NEPH) said it signed license & supply deal with Medica for exclusive global rights to sell the Italian company’s Medisulfone ultrafiltration technology.
Read more

 Toshiba’s Vital Images inks MR deal with Olea
Toshiba Medical Systems‘ (TYO:6502) Vital Images subsidiary and Olea Medical are partnering to integrate thin-client advanced neurological MR solutions on Vital Image’s VitreaAdvanced enterprise visualization software.
Read more

 SurgLine launches subsidiary to partner with spine surgeons
SurgLine Internationalsaid it’s formed SurgLine MDC Holdings LLC to pursue "cost containment of surgical implants in the operating room for hospitals and acute surgery centers," structured so that SMDC owns a minimum of 60% of each operating entity.
Read more

 Funding Roundup

 Analysts’ ups and downs

  • Abiomed (NSDQ:ABMD): Jefferies & Co. boosts price target from $25 to $28, maintains "buy" rating.
  • HeartWare International (NSDQ:HTWR): Zacks reiterates "neutral" rating, $70 price target.
  • Intuitive Surgical (NSDQ:ISRG): Barclays raises from "equal weight" to "overweight;" Zacks rates "#1 rank (strong buy)."
  • Kimberly-Clark (NYSE:KMB): Bank of America reiterates "buy" rating, raises price target from $80 to $84.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply